Bestat Participates in 2026 BIO International Convention to Expand North American Biotech Collaboration
Bestat Pharmaservices Corp. participated this year in the “Phoenix Biomedical Business Delegation” led by the Biomedical Industry Promotion Office of the Ministry of Economic Affairs (BPIPO), and joined the delegation in attending the 2026 BIO International Convention. During the event, Bestat set up a booth at the Taiwan Pavilion, engaging with global biopharmaceutical companies, research institutions, investment organizations, and industry partners to showcase the professional capabilities of Taiwan's CRO sector in clinical research services.
BIO International Convention is one of the most influential annual events in the global biopharmaceutical industry, bringing together innovation, research capabilities, and industry resources from around the world. Throughout the exhibition, Bestat introduced its experience and strengths in clinical trial execution, data management, statistical analysis, and integrated CRO services to international partners at the Taiwan Pavilion, while actively exploring future collaboration opportunities with potential partners.
This participation represents an important step in Bestat's continued expansion into the North American market and further demonstrates the growing international visibility of Taiwan's CRO service capabilities. Through face-to-face exchanges and business discussions, Bestat gained deeper insights into global biopharmaceutical trends while presenting the quality, efficiency, and professional value of Taiwan's clinical research teams to the international market.
As a Taiwan-based CRO with an active global outlook, Bestat has long been committed to supporting biopharmaceutical companies in advancing new drug development and clinical trial programs. Its participation in the 2026 BIO International Convention further strengthened Bestat's connection with the global industry value chain and created new possibilities for future cross-border collaboration and clinical development services.
Prior to the convention, Bestat also joined the Phoenix biomedical business delegation in visiting local biopharmaceutical organizations, gaining further understanding of the development landscape and innovation trends within North America's biomedical ecosystem. Through on-site exchanges and industry observations, Bestat not only broadened its international market perspective, but also accumulated valuable momentum for future collaboration and cross-border service development.
This participation also aligns with the United Nations Sustainable Development Goals (SDGs), particularly SDG 9: Industry, Innovation and Infrastructure and SDG 17: Partnerships for the Goals. Through international exhibitions and cross-border business exchanges, Bestat continues to promote innovation and advancement in biopharmaceutical R&D services, while strengthening the connection between Taiwan's biotech ecosystem and the global market through international collaboration.
Looking ahead, Bestat will continue to expand its global partnership network, integrate professional resources and industry relationships, support more biopharmaceutical companies in accelerating their R&D progress, and contribute to bringing Taiwan's biotech industry onto the international stage.
Bestat Pharmaservices Corp. participated this year in the “Phoenix Biomedical Business Delegation” led by the Biomedical Industry Promotion Office of the Ministry of Economic Affairs (BPIPO), and joined the delegation in attending the 2026 BIO International Convention. During the event, Bestat set up a booth at the Taiwan Pavilion, engaging with global biopharmaceutical companies, research institutions, investment organizations, and industry partners to showcase the professional capabilities of Taiwan's CRO sector in clinical research services.
BIO International Convention is one of the most influential annual events in the global biopharmaceutical industry, bringing together innovation, research capabilities, and industry resources from around the world. Throughout the exhibition, Bestat introduced its experience and strengths in clinical trial execution, data management, statistical analysis, and integrated CRO services to international partners at the Taiwan Pavilion, while actively exploring future collaboration opportunities with potential partners.
This participation represents an important step in Bestat's continued expansion into the North American market and further demonstrates the growing international visibility of Taiwan's CRO service capabilities. Through face-to-face exchanges and business discussions, Bestat gained deeper insights into global biopharmaceutical trends while presenting the quality, efficiency, and professional value of Taiwan's clinical research teams to the international market.
As a Taiwan-based CRO with an active global outlook, Bestat has long been committed to supporting biopharmaceutical companies in advancing new drug development and clinical trial programs. Its participation in the 2026 BIO International Convention further strengthened Bestat's connection with the global industry value chain and created new possibilities for future cross-border collaboration and clinical development services.
Prior to the convention, Bestat also joined the Phoenix biomedical business delegation in visiting local biopharmaceutical organizations, gaining further understanding of the development landscape and innovation trends within North America's biomedical ecosystem. Through on-site exchanges and industry observations, Bestat not only broadened its international market perspective, but also accumulated valuable momentum for future collaboration and cross-border service development.
This participation also aligns with the United Nations Sustainable Development Goals (SDGs), particularly SDG 9: Industry, Innovation and Infrastructure and SDG 17: Partnerships for the Goals. Through international exhibitions and cross-border business exchanges, Bestat continues to promote innovation and advancement in biopharmaceutical R&D services, while strengthening the connection between Taiwan's biotech ecosystem and the global market through international collaboration.
Looking ahead, Bestat will continue to expand its global partnership network, integrate professional resources and industry relationships, support more biopharmaceutical companies in accelerating their R&D progress, and contribute to bringing Taiwan's biotech industry onto the international stage.